This trial is exploring the use of a new PET tracer to study HIV in the body. It will enroll people who are early or late in their infection, or who are not on treatment.
1 Primary · 2 Secondary · Reporting Duration: 1-4 hours
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) · No Placebo Group · Phase 1
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: